Chifeng Addisun

Chifeng Addisun Pharmaceutical Co., Ltd., established in 2007 and a subsidiary of Hangzhou Minsheng Pharmaceutical Co., Ltd., is a leading Chinese pharmaceutical manufacturer specializing in hydroxyethyl starch (HES) series. The company is the first in China to industrialize medium molecular weight HES 200/0.5 and is currently the largest manufacturer of HES products in the country. Its primary products, HES 130/0.4 and HES 200/0.5, are widely used as plasma substitutes for treating hypovolemia and shock. Beyond its core HES portfolio, Chifeng Addisun is expanding into high-value-added APIs, including cephalosporin antibiotics, carbapenems, and targeted anti-tumor drugs through its Phase II production base. The company operates under strict GMP standards and serves both domestic and international markets.